Immatics (IMTX) Cash & Equivalents (2019 - 2025)
Immatics recorded quarterly Cash & Equivalents of $275.6 million in Q4 2025, little changed quarter-over-quarter from $276.8 million in Q3 2025, and up 18.04% year-over-year from $233.5 million in Q4 2024.
Immatics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $275.6 million for Q4 2025.
- In Q4 2025, Cash & Equivalents rose 18.04% year-over-year to $275.6 million; the TTM figure through Dec 2025 stood at $275.6 million (up 18.04% YoY), while the FY2025 annual figure was $267.5 million, up 14.57% from the prior year.
- Cash & Equivalents came in at $275.6 million for Q4 2025 at Immatics, roughly flat from $276.8 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $290.5 million in Q2 2025 to a low of $134.1 million in Q3 2022.
- A 5-year average of $211.5 million and a median of $235.2 million in 2024 frame the typical range for Cash & Equivalents.
- Across the five-year window, Cash & Equivalents jumped 119.54% in 2021 and plunged 45.21% in 2022, its largest moves.
- Immatics' Cash & Equivalents stood at $152.1 million in 2021, then retreated by 0.4% to $151.5 million in 2022, then jumped by 55.13% to $235.1 million in 2023, then fell by 0.68% to $233.5 million in 2024, then advanced by 18.04% to $275.6 million in 2025.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $275.6 million, $276.8 million, and $290.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | 275.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 275.58 Mn |
| Sep 30, 2025 | 276.77 Mn |
| Jun 30, 2025 | 290.50 Mn |
| Mar 31, 2025 | 249.03 Mn |
| Dec 31, 2024 | 233.46 Mn |
| Sep 30, 2024 | 239.93 Mn |
| Jun 30, 2024 | 235.27 Mn |
| Mar 31, 2024 | 237.34 Mn |
| Dec 31, 2023 | 235.06 Mn |
| Sep 30, 2023 | 161.68 Mn |
| Jun 30, 2023 | 161.73 Mn |
| Mar 31, 2023 | 159.41 Mn |
| Dec 31, 2022 | 151.53 Mn |
| Sep 30, 2022 | 134.09 Mn |
| Jun 30, 2022 | 141.91 Mn |
| Mar 31, 2022 | 149.26 Mn |
| Dec 31, 2021 | 152.14 Mn |
| Sep 30, 2021 | 244.74 Mn |
| Jun 30, 2021 | 249.92 Mn |
| Mar 31, 2021 | 250.33 Mn |
| Dec 31, 2020 | 247.44 Mn |
| Sep 30, 2020 | 120.72 Mn |
| Jun 30, 2020 | 113.84 Mn |
| Mar 31, 2020 | 114.10 Mn |
| Dec 31, 2019 | 114.40 Mn |
| Sep 30, 2019 | 43.80 Mn |
| Jun 30, 2019 | 44.23 Mn |